| Scorecard |
|---|
|
5 / 5 Stars
|
|
Lipper
5
5
4
5
4
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 1.0 | 1.0 |
| Stocks | 97.82 | 97.82 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 1.15 | 1.15 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.03 | 0.03 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Gilead Sciences Inc | GILD | 36.53 | 14.55 |
| Amgen Inc | AMGN | 21.82 | 14.2 |
| Celgene Corporation | CELG | 48.67 | 7.66 |
| Biogen Idec Inc | BIIB | 46.43 | 6.32 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 3.86 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.71 | 3.7 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 3.5 |
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 3.09 |
| Onyx Pharmaceuticals, Inc. | ONXX | 19.29 | 2.71 |
| Ironwood Pharmaceuticals, Inc. | IRWD | 32.94 | 2.03 |
